Fig. 3

Overall survival curves for negative and positive CD36 abundance according to the multiple Cox regression model corrected for age, FIGO stage, residual disease, and bevacizumab treatment (HR 1.91 [1.10–3.31], p = 0.021; x-axis in months; cf. Table 2). The dotted lines show the median survival times of both groups. As these survival curves are derived from a multiple Cox regression model, no censored patients are indicated.